Tobevibart and Elebsiran Phase 2 Trial for Hepatitis D Treatment
Ozempic and Cardiovascular Risk: New findings Demand Closer Scrutiny
What happened? A Closer Look at the SELECT Trial
A major clinical trial, the SELECT trial, has revealed a potential increased risk of serious cardiovascular events – including heart attack, stroke, and cardiovascular death – in adults with obesity and established cardiovascular disease who were treated with semaglutide (Ozempic) compared to those receiving a placebo. The trial involved over 17,600 participants across 30 countries and followed them for an average of 3.4 years. While semaglutide demonstrated important weight loss, this benefit was accompanied by a concerning signal regarding cardiovascular safety.
The Data: Key Findings from the SELECT trial
The study found that 6.5% of participants taking semaglutide experienced a major adverse cardiovascular event (MACE) compared to 4.9% in the placebo group.This translates to a hazard ratio of 1.33, indicating a 33% increased risk. However, it’s crucial to note that the trial did *not* meet its primary endpoint of reducing MACE, despite the significant weight loss observed in the semaglutide group (an average of approximately 15% of body weight).
| Outcome | Semaglutide group (%) | Placebo Group (%) | Hazard Ratio |
|---|---|---|---|
| Major Adverse Cardiovascular Event (MACE) | 6.5 | 4.9 | 1.33 |
| Cardiovascular Death | 3.7 | 2.9 | 1.29 |
| Non-Fatal Stroke | 2.6 | 1.7 | 1.54 |
| Non-Fatal Heart Attack | 1.9 | 1.3 | 1.47 |
Who is Affected? Understanding the Patient Population
This finding is particularly relevant for individuals with pre-existing cardiovascular disease. The SELECT trial specifically enrolled participants with a history of established cardiovascular disease,including heart attack,stroke,or peripheral artery disease. It’s significant to emphasize that the trial did *not* include patients with type 2 diabetes; all participants had obesity but not diabetes. This raises questions about the potential cardiovascular effects of semaglutide in different patient populations.
The average age of participants was 61, and approximately half were women. This demographic facts is important for understanding the generalizability of the findings to broader populations.
why Does This Matter? The Implications for Ozempic Use
The SELECT trial results challenge the widely held belief that semaglutide is a cardiovascularly neutral or even beneficial medication. While the drug has proven effective for weight loss and improving metabolic health, these benefits must now be weighed against the potential cardiovascular risks, especially in vulnerable populations. This necessitates a more cautious approach to prescribing semaglutide, particularly for individuals with established heart disease.